GSK and CureVac entered a strategic mRNA technology collaboration covering up to five mRNA-based vaccines and monoclonal antibodies for infectious diseases. GSK paid £104M (~$120M) upfront cash plus £30M (~$40M) reimbursable manufacturing reservation, with up to £294M (~$380M) in development/regulatory milestones plus tiered royalties. GSK also took a £130M (~$150M) equity stake.